^
    Back
    Association details:
    Biomarker:MLL rearrangement
    Cancer:Acute Lymphocytic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) +
    Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    1939 Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

    Published date:
    11/04/2020
    Excerpt:
    By multivariate analysis, baseline cytogenetics independently associated with worse survival included Ho-Tr [HR= 18.262 (95% CI= 5.935–56.196); p<0.001], and KMT2A [HR= 3.744 (95% CI= 1.256–11.165); p=0.018]....Our analysis identified baseline KMT2A rearrangements and Ho-Tr as independent predictive of poor outcome in pts with R-R ALL treated with the combination therapy of INO with mini-hyper-CVD with or without blinatumomab.
    Secondary therapy:
    Mini-HCVD